stockrowArvinas, Inc.
ARVNArvinas, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $262.6 million, roughly unchanged from fiscal 2024.
- Revenue
- −98.8%
- EPS
- −71.7%
- Free cash flow
- +82.8%
- Total debt
- −50.0%
Quarter to September 2026, against a year earlier
Follow ARVN
Alert me
Arvinas, Inc. (ARVN) Return on invested capital
Arvinas, Inc.'s return on invested capital over the twelve months to 30 September 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from 0.00% (fiscal 2025) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| BLSM BlossomHill Therapeutics, Inc. compare | 0.00% |
| RLMD Relmada Therapeutics, Inc. compare | 0.00% |
| PRTA Prothena Corporation plc compare | 0.00% |
| PHAT Phathom Pharmaceuticals, Inc. compare | 0.00% |
| TECX Tectonic Therapeutic, Inc. compare | 0.00% |
| INDP Indaptus Therapeutics, Inc. compare | 0.00% |
| ARVN Arvinas, Inc. | 0.00% |
| GYRE Gyre Therapeutics, Inc. compare | −9.94% |
| OCS Oculis Holding AG compare | −12,858.7% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)